1. Anticholinergic Drug Burden in Noncancer Versus Cancer Patients Near the End of Life 
Michael J. Hochman, BS, Arif H. Kamal, MD, MHS, Steven P. Wolf, MS, Greg P. Samsa, PhD, David C. Currow, BMed, MPH, FRACP, Amy P. Abernethy, MD, PhD, Thomas W. LeBlanc, MD, MA 
Journal of Pain and Symptom Management 
Volume 52, Issue 5, Pages e3 (November 2016)
DOI: /j.jpainsymman
Copyright © 2016 American Academy of Hospice and Palliative Medicine Terms and Conditions

2. Fig. 1
Distribution of mean ACL over performance status (AKPS) in a randomized controlled trial exploring statin discontinuation. a) Shows the distribution among 244 patients stratified by primary diagnosis (cancer vs. noncancer) with the number of patients in each column listed previously. b) and c) Show the distribution for cancer patients (n = 126) and noncancer patients (n = 118), respectively; medications are stratified by purpose (symptom or disease management). ACL = anticholinergic load; AKPS = Australia-modified Karnofsky Performance Status; DM = disease management; SM = symptom management.
Journal of Pain and Symptom Management  , e3DOI: ( /j.jpainsymman )
Copyright © 2016 American Academy of Hospice and Palliative Medicine Terms and Conditions